Diseases that primarily affect populations in low- and middle-income countries (LMICs) have a substantial toll on human health. Annually, more than one billion people are affected by a World Health Organization (WHO)-recognized neglected tropical disease (NTD), and hundreds of millions more are affected by other major conditions, such as malaria and tuberculosis. Yet, for many of these diseases, therapeutic options remain limited — either non-existent or hampered by safety and efficacy challenges — highlighting the urgent need for new treatments to complement preventive measures.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Acknowledgements
The authors thank L. Hegemann, B. Hughes and A. Probst for reviewing and providing feedback on the manuscript.
Competing Interests
The authors are employees of Novartis.
